Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from KMDA

Kamada (NASDAQ:KMDA) reiterated its full-year 2026 outlook after reporting first-quarter results that management said were in line with expectations, excluding a temporary shipment delay that shifted revenue into April. Chief Executive Officer Amir London said demand across the company’s product po

MarketBeat

Miele Just Made One Tiny Tweak to Its Pans That Makes So Much Sense (and Solves a Big Cooking Bugbear)

These new pots are perfect for open-plan kitchens and here's why

Livingetc

3 Pharma Stocks With May Potential

The pharma sector is poised for strong growth thanks to rising demand for personalized treatments, an aging population, advancements in pharma technology, and innovative approaches to drug discovery and manufacturing. Hence, investors could consider buying quality pharmaceutical stocks such as Zoetis (ZTS), Rigel Pharmaceuticals (RIGL), and Kamada (KMDA) with May…

StockNews.com

From analysis to the latest developments in health,
read the most diverse news in one place.

Contracts awarding work to private parties should not be cancelled without assigning reasons: SC

Supreme Court reserves judgement on contract cancellation, emphasizing private parties' right to reasons for termination.

The Hindu

Navigate to Success With These 4 Pharma Stocks to Buy

The pharmaceutical industry is expanding due to increased demand for healthcare products and technological advancements. Therefore, fundamentally strong pharma stocks Kamada (KMDA), Hypera (HYPMY), Eli Lilly (LLY) and Sanofi (SNY) might be ideal additions to your portfolio. Read on.

StockNews.com

3 Pharma Gems Driving Profits Now

The pharmaceutical industry is expected to expand rapidly in the coming years, driven by rising global medical needs and tech advancements. Therefore, fundamentally strong pharma stocks Kamada (KMDA), Voyager Therapeutics (VYGR) and OptiNose (OPTN) might be ideal additions to your portfolio. Read on.

StockNews.com

Will These 3 Pharma Stocks Become Gainers in 2024?

The pharmaceutical sector is anticipated to prosper due to the strong demand for drugs and therapies and the adoption of advanced technologies. So, let’s analyze whether pharmaceutical stocks Kamada (KMDA), Neurocrine Biosciences (NBIX), and Novartis (NVS) are well positioned to capitalize on the industry’s growth prospects.

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

3 Resilient Pharma Stocks to Buy This Week

Amid rising global medical needs and advancement in technology, the pharma industry is expected to witness robust growth in the coming years. Given this backdrop, resilient pharma stocks such as Spero Therapeutics (SPRO), GoodRx Holdings (GDRX) and Kamada (KMDA) might be solid buys now. Read on.

StockNews.com

3 Undervalued Pharma Stocks Worth Buying

With the growing prevalence of chronic diseases, the adoption of advanced digital technologies, and new drug discoveries, the pharmaceutical industry is set to witness significant growth this year and beyond. Thus, it could be wise to invest in quality pharma stocks Ipsen (IPSEY), Supernus (SUPN), and Kamada (KMDA), which are…

StockNews.com

2 Pharma Stocks to Watch Like a Hawk

From innovative drug pipelines to innovative research, the pharma sector offers a vast array of investment opportunities. Thus it would be wise to keep an eye on quality stocks Ipsen S.A.(IPSEY) and Kamada (KMDA), which hold considerable potential. Read more….

StockNews.com

No crack on main structure, Ultadanga flyover safe: West Bengal minister Firhad Hakim

KOLKATA: State urban development minister Firhad Hakim carried out an inspection of the VIP Road-bound arm of Ultadanga flyover following reports of twin cracks just before the exit point. After discussing the issue with KMDA engineers, Hakim assured that the crack between the approach embankment was superficial and did not…

The Times of India

Kolkata: Posta flyover likely to be razed by August-end

KOLKATA: The dismantling of Vivekananda Road flyover, which had collapsed during construction, is expected to be completed by the end of the month. Pointing out that the razing of the last 200m from the Malapara junction towards Posta market remained, a KMDA official said two deck slabs and four girders…

The Times of India

Kolkata: Cracks appear on VIP Road arm of Ultadanga flyover

KOLKATA: Motorists and locals have raised safety concerns over cracks on a section of the VIP Road-bound arm of the Ultadanga flyover that has been plagued with problems since it was commissioned 11 years ago. A girder in the EM Bypass-bound arm had collapsed in 2013. A crack had developed…

The Times of India

KMDA to repair 96-year-old Bagmari bridge

KOLKATA: The Kolkata Metropolitan Development Authority (KMDA) plans to take up repair work of the nearly 100-year-old Bagmari bridge over Circular canal on Maniktala main road which is an important connecting link between Kankurgachi and Maniktala.

The Times of India

Get all your
news in one place.

100's of premium titles.
One news app.

The Times of India

Kolkata Metropolitan Development Authority to repair Bagmari Bridge

KOLKATA: The Kolkata Metropolitan Development Authority (KMDA) plans to take up repair work of Bagmari Bridge over Circular canal on Maniktala Main Road.

The Times of India

Inform education department about any fest, cultural event: West Bengal govt to colleges

KOLKATA: The state government on Thursday said that all colleges will need to inform the state higher education department about all fests and cultural events being held by them. State education minister Bratya Basu said, “The Nazrul Mancha incident is unfortunate. It is undesirable. From now on the state will…

The Times of India

Kolkata: Chetla bridge dismantling nearly over

KOLKATA: The KMDA is on the verge of pulling down the damaged Chetla Lock Gate bridge over Tolly’s Nullah which will be reconstructed.

Benzinga

Earnings Preview For Kamada

Kamada (NASDAQ:KMDA) is set to give its latest quarterly earnings report on Tuesday, 2022-05-17. Here's what investors need to know before the announcement. Analysts estimate that Kamada will report an earnings per share (EPS) of $0.02.

Get all your
news in one place.

100's of premium titles.
One news app.

StockNews.com

5 Pharmaceutical Stocks Under $10 to Buy Right Now

Supportive federal policies to boost medical research and development, tech integration, and robust demand are factors that are expected to drive the long-term growth of the pharmaceutical industry. Thus, we think it could be wise to bet on quality pharmaceutical stocks Catalyst Pharmaceuticals (CPRX), Radius Health (RDUS), Assertio Holdings (ASRT),…

The Times of India

Prof abused for stopping duck feeding at Lake

Kolkata: The head of the zoology department of Diamond Harbour Fakir Chand College, who was on her morning walk in Rabindra Sarobar on Sunday, saw a woman feeding ducks chicken, rice and stale rotis. When the professor approached her, mentioning the signboards put up by KMDA that feeding ducks on…

Benzinga

Kamada: Q4 Earnings Insights

Kamada (NASDAQ:KMDA) reported its Q4 earnings results on Tuesday, March 15, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Benzinga

Earnings Preview: Kamada

Kamada (NASDAQ:KMDA) is set to give its latest quarterly earnings report on Tuesday, 2022-03-15. Here's what investors need to know before the announcement. Analysts estimate that Kamada will report an earnings per share (EPS) of $0.02.

The Times of India

West Bengal responds to citizens’ plea, to reopen parks from tomorrow

KOLKATA: Rabindra Sarobar, Subhas Sarobar and all major parks in Kolkata are set to reopen from Monday.

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Medical Pharmaceuticals

Medical – Pharmaceuticals

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.